Risk of Adult T-Cell Leukaemia/Lymphoma in HTLV-I Carriers

Kondo, Toshifumi; Kono, Hidehisa; Nonaka, Hiroshi; Miyamoto, Naoaki; Yoshida, Ryouichi; Bando, Fumihiro; Inoue, Hiroo; Miyoshi, Isao; Hinuma, Yorio; Hanaoka, Masao

doi:10.1016/s0140-6736(87)92359-2

Cited by 49 publications

(24 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the HTLV-1-infected individuals are asymptomatic virus carriers [Kondo et al, 1987]. In nonendemic regions, HTLV-1 has been detected in individuals originating from endemic areas, in their sexual partners, or in intravenous drug users.…”

Section: Introductionmentioning

confidence: 99%

Defective human T‐cell leukaemia virus type 1 (HTLV‐1) genomes: No evidence in serologically indeterminate german blood donors but new type detected in established cell lines

Morozov¹,

Ellerbrok

Fleischer

et al. 2001

Journal of Medical Virology

View full text Add to dashboard Cite

Individuals reactive in antibody screening tests (ELISA) and with one or more reactions to HTLV-1 proteins on Western blotting, but lacking the criteria of a confirmed HTLV infection, are not exceptional in regions with a low prevalence of HTLV-1/-2 infections. PCR analysis of these indeterminate samples, using "diagnostic" pol and tax sets of primers, give negative results. However, expression of HTLV-1 defective proviruses with internal deletions undetectable by PCR with diagnostic primers could have taken place. Seven German HTLV-1 ELISA-reactive blood donors, who showed reactivity also in Western blots against several viral proteins, and twenty haemophiliacs, were examined by nested PCR and/or PCR/Southern hybridisation with primers designed for detection of HTLV-1 defective proviruses. No HTLV-1-specific amplification products were obtained. However, HTLV-1 defective proviruses with large internal deletions were detected in four out of five cell lines established from symptomatic HTLV-1 cases and two in HUT-102 cells. In two amplicons, short inverted rRNA sequences between gag and env fragments of HTLV-1 defective proviruses were revealed. These results do not exclude the presence of defective HTLV-1 proviruses in individuals with indeterminate serology although this is unlikely.

show abstract

Section: Introductionmentioning

confidence: 99%

Defective human T‐cell leukaemia virus type 1 (HTLV‐1) genomes: No evidence in serologically indeterminate german blood donors but new type detected in established cell lines

Morozov¹,

Ellerbrok

Fleischer

et al. 2001

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Adult T-cell leukemia is an aggressive leukemia that develops after a long latency period in a small fraction of infected individuals (10,39,49,64,76). One HTLV-1 gene product, Tax, has been shown to activate transcription from the proviral promoter (reviewed in reference 20).…”

mentioning

confidence: 99%

Identification of Poly(ADP-Ribose) Polymerase as a Transcriptional Coactivator of the Human T-Cell Leukemia Virus Type 1 Tax Protein

Anderson

Scoggin

Simbulan-Rosenthal

et al. 2000

J Virol

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1) encodes a transcriptional activator, Tax, whose activity is believed to contribute significantly to cellular transformation. Tax stimulates transcription from the proviral promoter as well as from promoters for a variety of cellular genes. The mechanism through which Tax communicates to the general transcription factors and RNA polymerase II has not been completely determined. We investigated whether Tax could function directly through the general transcription factors and RNA polymerase II or if other intermediary factors or coactivators were required. Our results show that a system consisting of purified recombinant TFIIA, TFIIB, TFIIE, TFIIF, CREB, and Tax, along with highly purified RNA polymerase II, affinity-purified epitope-tagged TFIID, and semipurified TFIIH, supports basal transcription of the HTLV-1 promoter but is not responsive to Tax. Two additional activities were required for Tax to stimulate transcription. We demonstrate that one of these activities is poly(ADP-ribose) polymerase (PARP), a molecule that has been previously identified to be the transcriptional coactivator PC1. PARP functions as a coactivator in our assays at molar concentrations approximately equal to those of the DNA and equal to or less than those of the transcription factors in the assay. We further demonstrate that PARP stimulates Taxactivated transcription in vivo, demonstrating that this biochemical approach has functionally identified a novel target for the retroviral transcriptional activator Tax.

show abstract

“…In endemic areas, where most HTLV-I positives became infected from their mother as a young child, ATL incidence peaks after age 50 at a maximum of 1.2 per 1000 infected per year. 25 This suggests that those who become infected later in life do not have the time to develop the disease and indeed no definite case of ATL has been reported after infection in adulthood. 26 The attack rate of TSP/HAM seems to vary due to as yet unidentified cofactors.…”

Section: Risk Of Infection and Disease After Transfusionmentioning

confidence: 99%

Universal Screening for Anti‐HTLV Should Not be Introduced by Blood Banks in All Industrialised Countries

Goubau

Desmyter

1993

Reviews in Medical Virology

View full text Add to dashboard Cite

Risk of Adult T-Cell Leukaemia/Lymphoma in HTLV-I Carriers

Cited by 49 publications

References 2 publications

Defective human T‐cell leukaemia virus type 1 (HTLV‐1) genomes: No evidence in serologically indeterminate german blood donors but new type detected in established cell lines

Defective human T‐cell leukaemia virus type 1 (HTLV‐1) genomes: No evidence in serologically indeterminate german blood donors but new type detected in established cell lines

Identification of Poly(ADP-Ribose) Polymerase as a Transcriptional Coactivator of the Human T-Cell Leukemia Virus Type 1 Tax Protein

Universal Screening for Anti‐HTLV Should Not be Introduced by Blood Banks in All Industrialised Countries

Contact Info

Product

Resources

About